Abstract
The first clinical trials of praziquantel against Schistosoma japonicum infections in Japan were planned to assess tolerance only. Three double-blind studies against placebo involving a total of 51 patients were conducted with dosages of praziquantel of 1 × 20 mg/kg body weight, 2 × 20 mg/kg, 3 × 20 mg/kg given on one day.
The frequency of unwanted side effects was higher in the group of patients given praziquantel at a dose of 3 × 20 mg/kg than in all other drug- or placebo-treated patients. In general, the side effects, which included drowsiness, headache, lumbago, abdominal fullness, or epigastric discomfort, lasted for several hours but disappeared spontaneously. The results of laboratory tests showed no significant changes caused by treatment.
The overall assessment showed excellent or good tolerance in all patients treated with praziquantel at the lower dose levels. In those given 3 × 20 mg/kg, tolerance was excellent in 1 of 12 patients, good in 9, and fair in 2, whereas the respective placebo-treated group showed excellent tolerance in 3 of 12, good in 7, and fair in 2.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Davis A., Wegner D. H. Multicentre trials of praziquantel in human schistosomiasis: design and techniques. Bull World Health Organ. 1979;57(5):767–771. [PMC free article] [PubMed] [Google Scholar]
- OLIVER-GONZALEZ J. Anti-egg precipitins in the serum of humans infected with Schistosoma mansoni. J Infect Dis. 1954 Jul-Aug;95(1):86–91. doi: 10.1093/infdis/95.1.86. [DOI] [PubMed] [Google Scholar]